Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Is 18 Years and older in the United States or 20 Years and older in Japan~2. Has a pathologically documented advanced/unresectable or metastatic breast cancer~3. Documented HER3-positive disease measured by immunohistochemistry (IHC)~4. Has disease that is refractory to or intolerable with standard treatment, or for which standard treatment no longer is available~5. Has an Eastern Cooperative Oncology Group Performance Status 0-1~6. Has Left Ventricular Ejection Fraction ≥ 50%~7. Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1~   Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:~8. Has received 2-6 prior chemotherapy regimens for breast cancer, at least 2 of which were administered for treatment of advanced/unresectable or metastatic disease. At least 1 prior chemotherapeutic regimen must have included a taxane, administered in the neoadjuvant, adjuvant, or advanced setting. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)~   Additional Inclusion Criteria for Dose Expansion Part Only:~9. Is able to submit a fresh tumor biopsy sample prior to starting study treatment if not already submitted for HER3 expression~10. Has documented hormone (estrogen and/or progesterone) receptor (HR)-positive and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)~    Additional Inclusion Criteria for Dose Expansion Part TNBC cohort Only:~11. Has documented hormone (estrogen and progesterone) receptor (HR)-negative and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines~12. Has progressed after receiving 1 to 2 prior chemotherapy regimens for advanced/unresectable or metastatic breast cancer.~Key Exclusion Criteria:~1. Prior treatment with a HER3 antibody~2. Prior treatment with an antibody-drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201)~3. Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious cardiac arrhythmia requiring treatment~4. Has a medical history of myocardial infarction or unstable angina~5. Has a corrected QT prolongation to \> 450 millisecond (ms) in males and \> 470 ms in females~6. Has a medical history of clinically significant lung diseases (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period~7. Has clinically significant corneal disease~   Additional Exclusion Criteria for Dose Expansion Part:~8. Prior treatment with an govitecan derivative (eg, IMMU-132).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation Part (Type: EXPERIMENTAL): Participants receive U3-1402 from 1.6 mg/kg to 8.0 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
- Dose Finding Part (Type: EXPERIMENTAL): Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
- Dose Expansion Part (Type: EXPERIMENTAL): Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals. Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete